Copyright 2004 American Medical Association. All Rights Reserved.Applicable FARS/DFARS Restrictions Apply to Government Use.2004
We would like to comment on the recent article by Wirtitsch et al.1 The authors stated that our publication2 has been the only one to date indicating that irreversiblecorneal decompensation had been noted following the use of topical dorzolamidehydrochloride in patients with a compromised corneal endothelium. Their study,looking at patients with corneal guttata, is most appropriate as a model forproving the existence of this relationship, or lack thereof. Such a studyhad been suggested to us many years ago by William Bourne, MD (oral communication,October 2000), and we are pleased that it has finally been completed.
Epstein RJ, Brown SVL, Konowal A. Endothelial Changes Associated With Topical Dorzolamide Do Appear toBe Significant. Arch Ophthalmol. 2004;122(7):1089. doi:10.1001/archopht.122.7.1089-b